&nbsp;

Drugs Used:

ribociclib ,

fulvestrant

Quick Link(s):

Regimen Monograph

Apr 2021

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

VENE+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia

Exceptional Access Program

venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Drugs Used:

oBINutuzumab,

venetoclax

Quick Link(s):

Regimen Monograph

Jun 2023

Regimen

LENV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria

Drugs Used:

lenvatinib

Quick Link(s):

Regimen Monograph

Mar 2023

Drug

acalabrutinib

Other Name(s): Calquence®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2024

Regimen

AZCTVENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

DEXAPOMA+ISAT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

New Drug Funding Program

Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Exceptional Access Program

pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2024

Regimen

ENCO+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Drugs Used:

encorafenib,

cetuximab

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

RIPR

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours

Intent: Palliative

Funding:

Exceptional Access Program

ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib

Drugs Used:

ripretinib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

OSIM

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

Exceptional Access Program

osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations

Drugs Used:

osimertinib